Cosmo Pharmaceuticals S.p.A.
Via C. Colombo 1
I – 20020
36 articles with Cosmo Pharmaceuticals S.p.A.
Cosmo Pharmaceuticals N.V. invites investors, financial analysts as well as business and trade media to a conference call Q&A session on the 4th of May 2021 to discuss GI Genius™, the first device approved by the US Food and Drug Administration that uses artificial intelligence to help detect potential signs of colon cancer.
In 2020, Cosmo received European approval for Methylene Blue MMX®, received FDA approval for BYFAVO™, continued to execute its equity for product strategy and has returned to operating profit.
RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo Pharmaceuticals
New agreement further expands manufacturing capacity for orally-administered opaganib following positive top-line data from its Phase 2 COVID-19 study, progress with the ongoing global Phase 2/3 study, and amid the urgent need to address emerging viral strains [28-January-2021] TEL AVIV, Israel and RALEIGH, N.C. , Jan. 28, 2021 /PRNewswire/ -- RedHill Biopharma L
RedHill Biopharma and Cosmo Pharmaceuticals to Expand Strategic Partnership with Exclusive Licensing Agreement and Manufacturing Agreement for Multiple Products
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it has entered into a binding term sheet with Cosmo Pharmaceuticals N.V. for an exclusive licensing and manufacturing agreement for multiple products.
Acacia Pharma enters into strategic in-licensing, investment and loan transaction with Cosmo Pharmaceuticals N.V.
• Acacia Pharma has in-licensed exclusive US rights to ultra-short-acting sedative, ByFavo™ (remimazolam) from Cosmo adding to its portfolio of near-market products • Cosmo will make a €10 million equity investment in Acacia Pharma and provide a new €35 million loan facility to support commercial activities
RedHill Biopharma Announces $36 Million Strategic Investment by Cosmo Pharmaceuticals and U.S. Rights to Approved Travelers’ Diarrhea Drug AEMCOLO
RedHill Biopharma Ltd., a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, announced that it has entered into a strategic collaboration with Cosmo Pharmaceuticals N.V.
FDA accepts New Drug Application for Aemcolo (Rifamycin SV MMX®) and sets PDUFA Date for November 16, 2018
Upon FDA Approval, Aries Pharmaceuticals, Inc. to Lead U.S. Commercial Efforts.
FDA Grants Cosmo Pharmaceuticals Both QIDP and Fast Track Designations for Aemcolo (Rifamycin SV MMX) for Travelers' Diarrhea
Aries Pharmaceuticals, Cosmo's U.S. subsidiary based in San Diego, California, will lead the commercial sales and marketing for Aemcolo in the U.S.
Salix Pharmaceuticals, Ltd. Linked With Actavis After Calling Off Cosmo Pharmaceuticals S.p.A. Merger Amid Inversion Crackdown
AIMM Therapeutics in Strategic Partnership With Cosmo Pharmaceuticals S.p.A. to Combine Cosmo's Extended Release Technology & AIMM's High Quality Antibodies to Successfully Combat Gastrointestinal Disease
Cosmo Pharmaceuticals S.p.A. Announces Positive Top-Line Results in EU Phase III Clinical Study Evaluating Budesonide MMX In Ulcerative Colitis
Santarus Inc. and Cosmo Pharmaceuticals S.p.A.'s Anti-Inflammatory Drug Budesonide MMX Meets Late-Stage Goal
Cosmo Pharmaceuticals S.p.A. Reports Shire Pharmaceuticals Receives LIALDA(R) Paragraph IV Notice Letter from Zydus Pharmaceuticals (USA) Inc.
Cosmo Pharmaceuticals S.p.A. Reports Good 2009 Results -- Strategic Goals Met - Confident Outlook For 2010